CEO Ulf Hannelius spoke at Bridging the Gap, presented by Life Science Bridge. This year’s focus was women’s health, with autoimmune diseases like diabetes on the agenda. Diamyd Medical was one of the event sponsors.
Diamyd Medical’s ongoing Phase 3 trial includes clinics in both the U.S. and Europe, but the company is focusing its commercial efforts on the U.S. market.
“It’s the biggest market, and a single regulatory and insurance landscape makes it more efficient to launch there first,” Hannelius said. “If you need to choose, you choose the U.S.”
Read the article here
Silicon Valley Nordic Beat summarizes CEO Ulf Hannelius speech at the annual event presented by Life Science Bridge—a joint initiative between the regional chambers of commerce in San Diego, San Francisco/Silicon Valley, Minnesota, and New England.